Xenon Pharmaceuticals (XENE) Misses Q3 EPS by 6c

Xenon Pharmaceuticals (NASDAQ: XENE) reported Q3 EPS of ($0.57), $0.06 worse than the analyst estimate of ($0.51). Revenue for the quarter came in at $130 thousand versus the consensus estimate of $4.15 million.

For earnings history and earnings-related data on Xenon Pharmaceuticals (XENE) click here.

You May Also Be Interested In

• Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
• Xenon to present phase 3 azetukalner data at European Epilepsy Congress
• NewtekOne cuts EPS guidance, shifts focus to net interest income